The POSEIDON stratification - moving from poor ovarian response to low prognosis.
Bologna criteria
IVF/ICSI
POSEIDON
assisted reproduction
low-prognosis patients
poor ovarian response
Journal
JBRA assisted reproduction
ISSN: 1518-0557
Titre abrégé: JBRA Assist Reprod
Pays: Brazil
ID NLM: 101684552
Informations de publication
Date de publication:
27 04 2021
27 04 2021
Historique:
pubmed:
11
2
2021
medline:
2
2
2022
entrez:
10
2
2021
Statut:
epublish
Résumé
Poor ovarian response remains one of the most challenging tasks for an IVF clinician. In this review, we aim to highlight the ongoing research for optimizing the prognosis in poor ovarian response patients. The newly introduced POSEIDON criteria argue that the first step is to move from a poor response to a poor prognosis concept, while improving identification and stratification of the different sub-types of poor prognosis patients prior to ovarian stimulation. The immediate marker of success is the ability of the ovarian stimulation to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient. This surrogate marker of success should not replace live birth as the most important outcome, but it should be approached as a useful tool for clinicians to evaluate their strategy for achieving live birth in the shortest timespan possible in the individual patient/ couple.
Identifiants
pubmed: 33565297
doi: 10.5935/1518-0557.20200100
pmc: PMC8083858
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
282-292Références
J Assist Reprod Genet. 2015 Jun;32(6):931-7
pubmed: 25925345
Fertil Steril. 2013 Sep;100(3):712-7
pubmed: 23721713
Front Endocrinol (Lausanne). 2019 Sep 11;10:614
pubmed: 31572298
Reprod Biol. 2017 Mar;17(1):105-110
pubmed: 28173995
Hum Reprod. 2019 Jun 4;34(6):1030-1041
pubmed: 31125412
Hum Reprod Update. 2003 Jan-Feb;9(1):61-76
pubmed: 12638782
Fertil Steril. 2018 Sep;110(4):661-670.e1
pubmed: 30196963
Front Endocrinol (Lausanne). 2018 Aug 17;9:461
pubmed: 30174650
Panminerva Med. 2019 Mar;61(1):24-29
pubmed: 30021418
Fertil Steril. 2016 Jun;105(6):1452-3
pubmed: 26921622
Hum Reprod Update. 2016 Apr;22(3):306-19
pubmed: 26843539
Hum Reprod. 2019 Apr 1;34(4):659-665
pubmed: 30838395
Hum Reprod. 2016 Jul;31(7):1588-609
pubmed: 27207175
Hum Reprod. 2018 May 1;33(5):983-984
pubmed: 29596578
Front Endocrinol (Lausanne). 2018 Oct 17;9:589
pubmed: 30386293
Hum Reprod. 2011 Jul;26(7):1616-24
pubmed: 21505041
Hum Reprod. 2018 May 1;33(5):979-980
pubmed: 29596585
Int J Clin Exp Med. 2014 Apr 15;7(4):1128-34
pubmed: 24955194
Hum Reprod. 2011 Mar;26(3):671-7
pubmed: 21177311
Fertil Steril. 2017 Sep;108(3):393-406
pubmed: 28760517
Hum Reprod. 2017 Apr 1;32(4):853-859
pubmed: 28166330
Fertil Steril. 2011 Nov;96(5):1058-61.e7
pubmed: 22036048
Front Endocrinol (Lausanne). 2019 Jun 26;10:409
pubmed: 31293519
Hum Reprod Update. 2013 Mar-Apr;19(2):105-23
pubmed: 23255514
Reprod Biol Endocrinol. 2018 Mar 9;16(1):20
pubmed: 29523204
Hum Reprod. 2012 Dec;27(12):3481-6
pubmed: 22940767
Hum Reprod. 2017 Dec 01;32(12):2496-2505
pubmed: 29121326
Fertil Steril. 2013 Jul;100(1):100-7.e1
pubmed: 23548942
Hum Reprod. 2017 Dec 01;32(12):2485-2495
pubmed: 29121350
Hum Reprod. 2017 Mar 1;32(3):544-555
pubmed: 28137754
Hum Reprod. 2018 May 1;33(5):982-983
pubmed: 29596626
Fertil Steril. 2013 Feb;99(2):422-6
pubmed: 23084565
Reprod Biomed Online. 2003 Jun;6(4):439-43
pubmed: 12831590
F1000Res. 2016 Dec 23;5:2911
pubmed: 28232864
Hum Reprod. 2012 Apr;27(4):1066-72
pubmed: 22279090
Hum Reprod. 2011 Jul;26(7):1768-74
pubmed: 21558332
J Assist Reprod Genet. 2015 Dec;32(12):1709-12
pubmed: 26463876
Fertil Steril. 2018 Jan;109(1):59-60
pubmed: 29307403
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004379
pubmed: 20091563
Reprod Biomed Online. 2017 Jun;34(6):639-644
pubmed: 28366519
Hum Reprod. 2017 Dec 01;32(12):2506-2514
pubmed: 29121269
Front Endocrinol (Lausanne). 2019 Sep 19;10:642
pubmed: 31608011